Dr. Remo Moomiaie-Qajar, Founder, CEO, and Chairman of the Board at Axiom Biosciences, a clinical-stage biotechnology company developing next-generation regenerative therapies and targeted biologics by pairing its core cell therapy programs with AI-enabled drug design joins Enterprise Radio.
This episode of Enterprise Radio is in association with the Artificial Intelligence Channel.
Listen to interview with host Eric Dye & guest Dr. Remo Moomiaie-Qajar discuss the following:
- To start, you have a unique background as both a medical doctor and an entrepreneur. How has your firsthand clinical experience shaped your approach to leading a biotechnology company?
- As Founder, CEO, and Chairman, you wear many hats. What is the core philosophy or mission that keeps you and your team grounded as you scale the business?
- Cytonus Therapeutics recently rebranded to Axiom Biosciences. What was the catalyst for this change, and where is the company headed?
- Axiom is pairing regenerative medicine with AI-enabled drug design. How exactly does this “smart design” approach help ensure therapies reach their intended targets without harming healthy tissue?
- Could you walk us through how your experimental data and mechanistic AI work together? How does this combination help your team predict safety and efficacy much earlier in the drug development process?
- Axiom’s foundation is built on regenerative cell therapies, specifically your lead programs for neonatal brain injury. How does your advanced cellular engineering approach differ from traditional cell therapies?
- Looking to the future, what is the next major milestone or clinical breakthrough on the horizon for Axiom Biosciences that you are most excited about?
Dr. Remo Moomiaie-Qajar is trained in the Department of Surgery at Yale University and is a seasoned life science entrepreneur with over 17 years of experience building, investing in, and scaling biotechnology startups. He founded the company in 2018, originally spun out of UC San Diego as Cytonus, and recently orchestrated its strategic rebrand to Axiom Biosciences, pivoting the company from a single-asset developer into a high-value, multi-platform biotechnology leader.
Bringing a rare trifecta of experience as an academic researcher, physician, and startup founder, Dr. Moomiaie-Qajar holds multiple U.S. and international patents and a proven track record of taking technologies from venture stage to commercial market exit. Today, he is leveraging his extensive background in investment banking and public listings to lead Axiom through a historic, first-of-its-kind initial public offering for a U.S. biopharma company on the Hong Kong Stock Exchange.
Website: https://www.axiombio.co
Social Media Links:
Linkedin: linkedin.com/company/axiom-biosciences
X: x.com/AxiomBio_
People also listened to this: AI-native isn’t a technology transformation. It’s an organizational transformation.
Podcast: Play in new window | Download (Duration: 20:29 — 18.8MB) | Embed
Subscribe: Apple Podcasts | Spotify | iHeartRadio | TuneIn | RSS | More
